Cargando…
Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225924/ https://www.ncbi.nlm.nih.gov/pubmed/30465016 http://dx.doi.org/10.1212/NXI.0000000000000439 |
| _version_ | 1783369873280204800 |
|---|---|
| author | Hottinger, Andreas F. de Micheli, Rita Guido, Vanessa Karampera, Alexandra Hagmann, Patric Du Pasquier, Renaud |
| author_facet | Hottinger, Andreas F. de Micheli, Rita Guido, Vanessa Karampera, Alexandra Hagmann, Patric Du Pasquier, Renaud |
| author_sort | Hottinger, Andreas F. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6225924 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-62259242018-11-21 Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis Hottinger, Andreas F. de Micheli, Rita Guido, Vanessa Karampera, Alexandra Hagmann, Patric Du Pasquier, Renaud Neurol Neuroimmunol Neuroinflamm Clinical/Scientific Notes Lippincott Williams & Wilkins 2018-01-11 /pmc/articles/PMC6225924/ /pubmed/30465016 http://dx.doi.org/10.1212/NXI.0000000000000439 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
| spellingShingle | Clinical/Scientific Notes Hottinger, Andreas F. de Micheli, Rita Guido, Vanessa Karampera, Alexandra Hagmann, Patric Du Pasquier, Renaud Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis |
| title | Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis |
| title_full | Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis |
| title_fullStr | Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis |
| title_full_unstemmed | Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis |
| title_short | Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis |
| title_sort | natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis |
| topic | Clinical/Scientific Notes |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225924/ https://www.ncbi.nlm.nih.gov/pubmed/30465016 http://dx.doi.org/10.1212/NXI.0000000000000439 |
| work_keys_str_mv | AT hottingerandreasf natalizumabmaycontrolimmunecheckpointinhibitorinducedlimbicencephalitis AT demichelirita natalizumabmaycontrolimmunecheckpointinhibitorinducedlimbicencephalitis AT guidovanessa natalizumabmaycontrolimmunecheckpointinhibitorinducedlimbicencephalitis AT karamperaalexandra natalizumabmaycontrolimmunecheckpointinhibitorinducedlimbicencephalitis AT hagmannpatric natalizumabmaycontrolimmunecheckpointinhibitorinducedlimbicencephalitis AT dupasquierrenaud natalizumabmaycontrolimmunecheckpointinhibitorinducedlimbicencephalitis |